
Oriental Hotels Ltd. reported a 44% year-on-year surge in Q3 net profit to ₹20.7 crore, driving its shares up by over 12% on strong operational performance.
Infosys may lose $150 million in annual revenue as German automaker Daimler considers a new vendor for a key part of their $3.2 billion IT contract.
Indo Thai Securities reports a massive 1203% surge in Q3FY26 net profit to ₹17.39 crore, driven by significant fair value gains and strong revenue growth.
Defrail Technologies' ₹13.76 crore SME IPO closed with a massive 78.11 times oversubscription, driven by strong demand from HNI and retail investors.
The Delhi High Court has permitted Zydus Lifesciences to launch a biosimilar of the expensive cancer drug Nivolumab, prioritizing public interest over patent rights.
Anand Rathi Wealth reports a 30% year-on-year increase in net profit to ₹100.10 crore for Q3 FY26, driven by strong revenue growth and expanding assets under management.
Tata Motors reports its highest-ever quarterly sales of 171,013 units in Q3 FY26, a 22.3% year-on-year growth, driven by strong SUV and EV demand.
Bank of Maharashtra's board meets on January 13, 2026, to approve Q3 FY26 results and consider an interim dividend, following strong Q2 performance and robust business growth.
Bank of Maharashtra's board will meet on January 13, 2026, to approve Q3 FY26 results and consider an interim dividend amid strong business growth.
Vedanta's stock price hits a new high following the National Company Law Tribunal's approval for its demerger into five separate listed entities, prompting positive brokerage revisions.
Navkar Corporation's stock price surged on January 13, 2026, with unusually high trading volume, following a reported turnaround in quarterly profits and strong revenue growth.
Kotak Mahindra Bank has confirmed January 14, 2026, as the record date for its 1:5 stock split, a move aimed at enhancing liquidity and making shares more accessible.
GTPL Hathway reported a 12% year-on-year revenue increase to ₹964.9 crore in Q2 FY26, though net profit declined amid challenges in its cable TV segment.
Tata Consultancy Services reported a sequential profit decline in Q3 FY26 due to one-time costs but surprised investors with a substantial ₹57 per share dividend.
Zydus Lifesciences' subsidiary Sentynl Therapeutics receives FDA acceptance for its resubmitted New Drug Application for CUTX-101, a treatment for the rare Menkes disease.
Balu Forge Industries shares fell 20% to the lower circuit after reports emerged of Income Tax Department search operations at its premises, creating market uncertainty.